Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

This study has been completed.
Information provided by:
Jonsson Comprehensive Cancer Center Identifier:
First received: June 6, 2002
Last updated: January 7, 2013
Last verified: January 2013

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic colorectal cancer.

Condition Intervention Phase
Colorectal Cancer
Biological: panitumumab
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: An Open Label Phase II Clinical Trial To Evaluate The Safety And Efficacy Of ABX-EGF In Patients With Metastatic Colorectal Carcinoma

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 44
Study Start Date: July 2002
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the response rate of patients with metastatic colorectal cancer treated with monoclonal antibody ABX-EGF.
  • Determine the additional measures of clinical efficacy of this drug, in terms of progression-free survival, overall survival, and time to treatment failure, in these patients.
  • Determine the safety of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive monoclonal antibody ABX-EGF IV over 1 hour weekly on weeks 1-8. Treatment repeats every 8 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks, every 3 months for 1 year, and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 20-100 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed colorectal carcinoma

    • Diagnosed by fine-needle aspirate or tissue biopsy
    • Metastatic disease
    • No squamous cell carcinoma
  • Relapsed or refractory after prior chemotherapy with irinotecan and a fluoropyrimidine (i.e., fluorouracil, capecitabine, or ftorafur with or without leucovorin calcium) given concurrently or sequentially

    • Progressive disease within 2 months of last dose of this prior chemotherapy for metastatic disease OR
    • Evidence of relapse within 12 months after last dose of adjuvant therapy
  • Bidimensionally measurable disease
  • Overexpression of epidermal growth factor r (EGFr) by immunohistochemistry

    • Must be 2+ or 3+ in at least 10% of evaluated tumor cells
  • No known brain metastases



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified


  • Absolute neutrophil count greater than 1,500/mm3
  • Platelet count greater than 100,000/mm3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 3 times ULN
  • Alkaline phosphatase no greater than 3 times ULN


  • Creatinine no greater than 2.2 mg/dL


  • LVEF at least 45% by MUGA
  • No myocardial infarction within the past year


  • HIV negative
  • No other malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix
  • No chronic medical or psychiatric condition that would preclude study
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 1 month after study


Biologic therapy:

  • No prior EGFr-targeting agents or biological agents with antitumor activity


  • See Disease Characteristics
  • At least 30 days since prior systemic chemotherapy
  • No more than 2 prior fluoropyrimidine regimens (e.g., fluorouracil and leucovorin calcium followed by capecitabine)
  • No other prior chemotherapy, except leucovorin calcium, for colorectal carcinoma

Endocrine therapy:

  • Not specified


  • At least 30 days since prior radiotherapy


  • Not specified


  • At least 30 days since other prior anticancer therapy
  • No prior investigational drug with potential antitumor activity
  • No other concurrent investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00039273

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Joel Randolph Hecht, MD Jonsson Comprehensive Cancer Center
  More Information

Additional Information:
Meropol NJ, Berlin J, Hecht JR, et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1026, 256, 2003. Identifier: NCT00039273     History of Changes
Other Study ID Numbers: CDR0000069368, UCLA-0112063, IMMUNEX-054-0005, NCI-G02-2073
Study First Received: June 6, 2002
Last Updated: January 7, 2013
Health Authority: United States: Federal Government

Keywords provided by Jonsson Comprehensive Cancer Center:
stage IV colon cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases processed this record on November 20, 2014